124 related articles for article (PubMed ID: 22022936)
1. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer.
Cho WC
Expert Rev Mol Diagn; 2011 Nov; 11(8):763-6. PubMed ID: 22022936
[No Abstract] [Full Text] [Related]
2. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer.
Zandberga E; Kozirovskis V; Ābols A; Andrējeva D; Purkalne G; Linē A
Genes Chromosomes Cancer; 2013 Apr; 52(4):356-69. PubMed ID: 23404859
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma.
Gao W; Liu L; Lu X; Shu Y
Clin Lung Cancer; 2011 Jan; 12(1):14-7. PubMed ID: 21273174
[No Abstract] [Full Text] [Related]
4. Molecular marker analyses from the SATURN trial.
Brugger W
Clin Adv Hematol Oncol; 2012 Jan; 10(1):33-4. PubMed ID: 22398805
[No Abstract] [Full Text] [Related]
5. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
Gao W; Xu J; Shu YQ
Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
[TBL] [Abstract][Full Text] [Related]
6. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens.
van den Berg RM; Snijders PJ; Grünberg K; Kooi C; Spreeuwenberg MD; Meijer CJ; Postmus PE; Smit EF; Steenbergen RD
Lung Cancer; 2011 Jun; 72(3):316-21. PubMed ID: 21067843
[TBL] [Abstract][Full Text] [Related]
9. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
Cho WC; Chow AS; Au JS
Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
[TBL] [Abstract][Full Text] [Related]
10. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Boeri M; Pastorino U; Sozzi G
Cancer J; 2012; 18(3):268-74. PubMed ID: 22647364
[TBL] [Abstract][Full Text] [Related]
11. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray.
Ye Y; Wang D; Su C; Rong T; Guo A
Genet Mol Res; 2009 Dec; 8(4):1509-18. PubMed ID: 20082263
[TBL] [Abstract][Full Text] [Related]
12. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
da Cunha Santos G; Saieg MA; Geddie W; Leighl N
Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
[TBL] [Abstract][Full Text] [Related]
14. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutation testing for squamous cell lung carcinoma.
Liam CK; Leow HR; Pang YK
J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
[No Abstract] [Full Text] [Related]
16. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.
Frattini M; Balestra D; Verderio P; Gallino G; Leo E; Sozzi G; Pierotti MA; Daidone MG
J Clin Oncol; 2005 May; 23(13):3163-4; author reply 3164-5. PubMed ID: 15860889
[No Abstract] [Full Text] [Related]
17. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
[TBL] [Abstract][Full Text] [Related]
18. Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis.
Li Y; Liang L; Zhang CY
Anal Chem; 2013 Dec; 85(23):11174-9. PubMed ID: 24215456
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
[TBL] [Abstract][Full Text] [Related]
20. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
